• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Clinical Pathways


Steven Peskin, MD, MBA, FACP: We have not embraced clinical pathways in the way that we’re saying that we’re working with a particular third-party clinical pathway company.

What we are doing is working around episode-of-care type of contracts. Within those clinical organizations, they are, in turn, setting certain standards and looking at certain pathways. They’re looking at their clinicians in their organizations [to see] if they’re following certain protocols—[for example, regarding] the judicious or injudicious use of PET/CT (positron emission tomography/computed tomography) scans, and which therapies are being used in what situations.

So we have not, as an organization, embraced a particular clinical pathway construct. Though we certainly see the great value in evidence-based care (evidence-based medicine), we’re not specifically focused on a particular clinical pathway, [having a] third party work with us, or [establishing] our own approach to designated clinical pathways.

Related Videos
Fabiola, Molina, MD, MHS | Image Credit: Yale School of Medicine
James Robinson, PhD, MPH, University of California, Berkeley
Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"
Camilla Levister
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Douglas K. Marks, MD | Image credit: NYU Langone Health
Related Content
© 2024 MJH Life Sciences
All rights reserved.